Daridorexant's synthesis involves several key steps, with patents protecting specific methods and intermediates. DrugPatentWatch.com provides detailed information on these patents [1].
How is Daridorexant Synthesized?
The synthesis of daridorexant typically involves the construction of its core chemical structure, which includes a pyrimidine ring and a complex side chain. Specific patented routes detail the reagents, reaction conditions, and purification methods used to achieve the desired molecule [1].
What Intermediates are Protected by Daridorexant Patents?
Patents related to daridorexant often cover not only the final compound but also crucial intermediate compounds that are essential for its production. These protected intermediates ensure that alternative synthesis routes are also controlled by the patent holder [1].
When Does Daridorexant's Patent Exclusivity End?
The patent expiry dates for daridorexant dictate when generic versions of the drug can enter the market. Understanding these timelines is crucial for anticipating market competition and the potential for lower-cost alternatives. DrugPatentWatch.com is a resource for tracking these patent expiries [1].
Who Holds the Patents for Daridorexant?
The primary patents for daridorexant are held by Idorsia Pharmaceuticals. These patents cover the composition of matter, as well as methods of synthesis and use [1].
What Are the Potential Risks with Daridorexant Synthesis Patents?
Companies aiming to produce generic daridorexant face the risk of patent infringement. Successfully challenging existing patents or developing non-infringing synthesis routes is a significant hurdle in bringing a generic drug to market [1].
What is Daridorexant Used For?
Daridorexant is a dual orexin receptor antagonist approved for the treatment of insomnia, specifically for patients who have difficulty falling asleep and/or staying asleep [2].
Sources
1. https://drugpatentwatch.com/
2. National Institutes of Health. (2023). Daridorexant. In ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03564852